SCHEMBL15096076

SCHEMBL15096076

Cc1cc(N2CCN(C(=O)Cn3nc(-c4ncc[nH]4)c4c(N)ncnc43)CC2)c(F)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 3/20 0.46
ADAMTS5 Q9UNA0 1/20 0.41
TGFBR1 P36897 5/20 0.37
FGFR1 P11362 4/20 0.36
FGFR4 P22455 4/20 0.36
KCNH2 Q12809 2/20 0.35
FGFR2 P21802 3/20 0.35
FGFR3 P22607 3/20 0.35
JAK3 P52333 2/20 0.35
JAK2 O60674 1/20 0.35
ALDH1A1 P00352 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 1/20 0.34
HPGD P15428 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1846775 0.90 CCR1 (0.55) CCR1FGFR1FGFR4KCNH2FGFR2
SCHEMBL1848601 0.90 CCR1 (0.55) CCR1FGFR1FGFR4KCNH2FGFR2
SCHEMBL15096077 0.89 CCR1 (0.37) CCR1TGFBR1KCNH2
SCHEMBL1847193 0.88 CCR1 (0.46) CCR1TGFBR1FGFR1FGFR4KCNH2
SCHEMBL15096079 0.86 CCR1 (0.58) CCR1TGFBR1FGFR1FGFR4KCNH2
SCHEMBL10063572 0.83 CCR1 (0.66) CCR1ADAMTS5ALDH1A1SMN1; SMN2LMNA
SCHEMBL26188300 0.81 CCR1 (0.47) CCR1LMNAHTTMAPT
SCHEMBL3225786 0.81 CCR1 (0.53) CCR1ALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL1637661 0.80 CCR1 (0.72) CCR1KCNH2
SCHEMBL3226671 0.80 CCR1 (0.45) CCR1FGFR1FGFR4FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170290808-A1 REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS CHEMOCENTRYX, INC. 2017-10-12 US disclosed
US-8946240-B2 4-amino-3-(imidazolyl)-pyrazolo[3,4-D]pyrimidines CHEMOCENTRYX, INC. (US) 2015-02-03 US disclosed
US-20130178623-A1 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES CHEMOCENTRYX, INC. (US) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170290808-A1 REDUCING TUMOR BURDEN BY ADMINISTERING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS CCR1, CCRL2, CCR3 CCR1 1/4885ADAMTS5 1171/4885TGFBR1 175/4885
US-20130178623-A1 4-AMINO-3-(IMIDAZOLYL)-PYRAZOLO[3,4-D]PYRIMIDINES CCR1, CCR3, CCR4 CCR1 1/4885ADAMTS5 4101/4885TGFBR1 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.